



Edgar Filing: AMICUS THERAPEUTICS INC - Form 8-K

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 2.02. Results of Operations and Financial Condition.

On August 7, 2018, Amicus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second fiscal quarter, ended June 30, 2018. A copy of this press release is attached hereto as Exhibit 99.1. The Company will host a conference call and webcast on August 7, 2018 to discuss its second quarter results of operations. A copy of the conference call presentation materials is also attached hereto as Exhibit 99.2.

In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K and the Exhibits shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No. Description

99.1      Press Release dated August 7, 2018.

99.2      August 7, 2018 Conference Call Presentation Materials

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMICUS THERAPEUTICS, INC.

Date: August 7, 2018 By: /s/ Ellen S. Rosenberg  
Name: Ellen S. Rosenberg  
Title: General Counsel and Corporate Secretary